I’ll have more soon — on Off the road now — at a board meeting today, but BMS’s nivolumab, branded as Opdivo®, still holds the lead in this fairly high burden indication.
This morning’s announcement means that the FDA has blessed pembrolizumab, or Keytruda® with priority review status — and with an aspirational approval date of August 9, 2016. We shall see.
From an earlier note, at OncLive then:
. . . .Both nivolumab and pembrolizumab have demonstrated activity in patients with head and neck cancer. The phase III CheckMate-141 trial, which examined the anti–PD-1 agent nivolumab versus investigator’s choice of cetuximab (Erbitux), methotrexate, or docetaxel in patients with platinum-refractory squamous cell carcinoma of the head and neck, was stopped early after it was determined nivolumab had met its primary endpoint of overall survival. . . .
This particular race will be neck-and-neck (rim-shot!) — but overall, BMS still holds a significant lead. Travel safely one and all!